Advisory Committee To Discuss Changes To CMS’ Trial Payment Policy
This article was originally published in The Gray Sheet
Executive Summary
CMS will seek guidance from the Medicare Coverage Advisory Committee (MCAC) Dec. 13 on revising its policy for reimbursing certain device clinical trial costs
You may also be interested in...
Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
CDRH Unveils Postmarket Safety “Action Items”
FDA's plan to strengthen postmarket device safety by making better use of postmarket data includes modifying its organizational infrastructure, updating adverse event reporting practices and potentially increasing the use of fines for certain types of industry noncompliance
CMS Should Clarify Coverage For Device Trials, Manufacturers Say
Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies